← 홈

Antibody

45개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 45개
AntibodystaleGerman CLL Study GroupPhase 2

Alemtuzumab i.v. (Alemtuzumab i.v.)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleGerman CLL Study GroupPhase 2

Alemtuzumab s.c. (Alemtuzumab s.c.)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAmgenPhase 2

Blinatumomab (BLINCYTO, BLINCYTO (Blinatumomab))

Mixed Phenotype Acute Leukemia (MPAL); Measurable Residual Disease (MRD) · Mixed Phenotype Acute Leukemia (MPAL)

#MixedPhenotypeAcuteLeukemiaMPAL#Antibody#Phase2#항체#면역항체+3
효능 ORR 11.1%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bendamustine, Rituximab, Lenalidomide (Bendamustine, Rituximab, Lenalidomide)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab plus chemotherapy according to the national treatment program)

T-Lymphocytic Leukemia, Acute · T-Lymphocytic Leukemia, Acute

#T-LymphocyticLeukemiaAcute#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleAssistance Publique - Hôpitaux …Phase 2

nivolumab (Opdivo, Decreasing starting times for beginning nivolumab, Time to Event Continual Reassessment Method (TITE-CRM, Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ))

B Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · B Acute Lymphoblastic Leukemia

#BAcuteLymphoblasticLeukemia#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleBiogenPhase 2

FCR + Lumiliximab (FCR + Lumiliximab)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 1

HDMP + rituximab as a means of debulking prior to initiating venetoclax. (HDMP + rituximab as a means of debulking prior to initiating venetoclax.)

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia or Small Ly

#ChronicLymphocyticLeukemiaorSmal#Antibody#Phase1#항체#면역항체+2
효능 ORR 1%임상시험 1상태 RECRUITING
AntibodystalePfizerPhase 3

Inotuzumab (Inotuzumab)

Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

Intrathecal Rituximab (Intrathecal Rituximab)

Leukemia; Lymphoid Malignancies · Leukemia

#Leukemia#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleGeorgetown UniversityPhase 1

Lenalidomide, Ibrutinib, Rituximab (Lenalidomide, Ibrutinib, Rituximab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleNational Cancer Institute (NCI)Phase 1

Moxetumomab Pasudotox-tdfk (Moxetumomab Pasudotox-tdfk)

Hairy Cell Leukemia · Hairy Cell Leukemia

#HairyCellLeukemia#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleGenta IncorporatedPhase 2

Oblimersen-rituximab-fludarabine (Oblimersen-rituximab-fludarabine)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRegeneron PharmaceuticalsPhase 1

Odronextamab multiple dose levels (Odronextamab multiple dose levels)

Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleAbbViePhase 1

Pivekimab Sunirine (Pivekimab Sunirine)

Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Rituximab (Mabthera, Rituximab, Rituximab (Mabthera) , FFP (Fresh Frozen Plasma))

Advanced Refractory Chronic Lymphocytic Leukemia · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Rituximab+mVPDL (Rituximab+mVPDL)

Precursor Cell Lymphoblastic Leukemia-Lymphoma · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C (Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C)

B-cell Non Hodgkin Lymphoma; Mature B-cell Leukemia Burkitt-type · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodyBiologicstaleSeagen Inc.Phase 2

anti-huCD40 mAb (SGN-40, SGN-40 (anti-huCD40 mAb))

Leukemia, Lymphocytic, Chronic · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleInstitute of Hematology & Blood…Phase 2

Zanubrutinib, Fludarabine, cyclophosphamide and rituximab (Zanubrutinib, Fludarabine, cyclophosphamide and rituximab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE

2 / 3 페이지

← 이전다음 →